Cherry SE [ISIN: DE000A3CRRN9], a global manufacturer of computer input devices and digital solutions for the healthcare sector, has convened an Extraordinary General Meeting (EGM) scheduled for May 22, 2026, to address critical financial restructuring and growth initiatives. The company announced the move in a press release on April 14, 2026, outlining plans to restore its capital market eligibility through a reverse share split and evaluation of financing options.
The EGM will seek shareholder approval for a reverse stock split at a ratio of 4:1. This measure is intended to offset accumulated balance sheet losses and re-establish the company's compliance with capital market requirements. According to the release, the reverse split is necessary to create the prerequisites for potential financing measures that would support further restructuring and growth. The company is currently evaluating various financing options to execute these initiatives.
The timing of the EGM is driven by delays in the publication of Cherry SE's annual financial report. The change of auditor and first-time audit procedures have required more time than originally anticipated, pushing the release of the annual report to July 15, 2026. Preliminary results for the 2025 fiscal year were published on March 5, 2026. The full Q1/2025 quarterly financial report will be available for download on Cherry SE's investor relations website from May 7, 2026.
By convening the EGM separately, the company ensures that the restoration of capital market eligibility can proceed independently of the revised reporting timeline. This strategic decision allows Cherry SE to address its financial standing without waiting for the delayed annual report. The company emphasized that the reverse split is a key step to regain eligibility for potential financing and to support ongoing restructuring efforts.
Cherry SE is known for its computer input devices such as keyboards, mice, microphones, and headsets for office, gaming, and industrial applications, as well as digital healthcare solutions. Founded in 1953, the company has operational headquarters in Auerbach, Germany, with production and development sites in Germany, China, and Austria, and sales offices across Europe, the US, and Asia. More information is available at https://ir.cherry.de/en/.
The EGM's outcome will be closely watched by investors as Cherry SE navigates its financial restructuring. The reverse split aims to reduce the number of shares outstanding, potentially increasing the stock price and attracting institutional investors. However, reverse splits can also signal financial distress, and the company's ability to secure financing and execute growth plans will be critical for long-term recovery.
